Cytosorbents Begin Period Cash Flow vs Capital Expenditures Analysis

CTSO Stock

USD 0.94 0.04 4.44%

Cytosorbents Crp financial indicator trend analysis is way more than just evaluating Cytosorbents Crp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cytosorbents Crp is a good investment. Please check the relationship between Cytosorbents Crp Begin Period Cash Flow and its Capital Expenditures accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.

Begin Period Cash Flow vs Capital Expenditures

Begin Period Cash Flow vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cytosorbents Crp Begin Period Cash Flow account and Capital Expenditures. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Cytosorbents Crp's Begin Period Cash Flow and Capital Expenditures is 0.89. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Cytosorbents Crp, assuming nothing else is changed. The correlation between historical values of Cytosorbents Crp's Begin Period Cash Flow and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Cytosorbents Crp are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Begin Period Cash Flow i.e., Cytosorbents Crp's Begin Period Cash Flow and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

0.89

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Cytosorbents Crp to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Cytosorbents Crp operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most indicators from Cytosorbents Crp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cytosorbents Crp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.At this time, Cytosorbents Crp's Selling General Administrative is very stable compared to the past year. As of the 29th of December 2024, Issuance Of Capital Stock is likely to grow to about 17.5 M, while Tax Provision is likely to drop (854.4 K).

	2021	2022	2023	2024 (projected)
Other Operating Expenses	62.9M	60.9M	67.6M	70.9M
Total Revenue	40.1M	29.4M	36.3M	38.2M

Other Operating Expenses Total Revenue

Cytosorbents Crp fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Net Debt	Retained Earnings	Cash	Common Stock Total Equity	Common Stock Shares Outstanding	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Other Current Liab	Total Stockholder Equity	Property Plant And Equipment Net	Non Current Assets Total	Cash And Short Term Investments	Non Current Liabilities Total	Other Stockholder Equity	Common Stock	Accounts Payable	Non Currrent Assets Other	Other Current Assets	Good Will	Intangible Assets	Other Assets	Property Plant Equipment
Total Assets		0.55	0.83	-0.68	-0.78	0.89	-0.36	0.86	0.62	0.68	0.92	0.94	0.93	0.7	0.76	0.89	0.36	0.87	-0.35	0.69	0.63	0.82	0.89	0.94	0.89	0.77
Short Long Term Debt Total	0.55		0.84	0.2	-0.86	0.17	-0.42	0.83	0.86	0.83	0.27	0.76	0.27	0.83	0.84	0.17	0.71	0.66	-0.4	0.81	0.34	0.56	0.82	0.78	0.22	0.79
Total Current Liabilities	0.83	0.84		-0.25	-0.93	0.56	-0.4	0.94	0.84	0.82	0.63	0.9	0.61	0.82	0.86	0.56	0.58	0.82	-0.38	0.92	0.49	0.62	0.96	0.92	0.6	0.84
Net Debt	-0.68	0.2	-0.25		0.17	-0.93	0.16	-0.31	0.05	0.03	-0.89	-0.45	-0.86	0.0	-0.07	-0.93	0.26	-0.47	0.17	-0.07	-0.55	-0.45	-0.33	-0.43	-0.82	-0.15
Retained Earnings	-0.78	-0.86	-0.93	0.17		-0.48	0.3	-0.96	-0.84	-0.83	-0.56	-0.86	-0.55	-0.83	-0.86	-0.48	-0.63	-0.88	0.28	-0.82	-0.47	-0.69	-0.92	-0.89	-0.49	-0.78
Cash	0.89	0.17	0.56	-0.93	-0.48		-0.29	0.61	0.29	0.28	0.99	0.73	0.96	0.31	0.38	1.0	0.03	0.71	-0.29	0.38	0.69	0.67	0.64	0.73	0.9	0.45
Common Stock Total Equity	-0.36	-0.42	-0.4	0.16	0.3	-0.29		-0.49	-0.03	-0.23	-0.33	-0.45	-0.41	-0.24	-0.27	-0.3	0.23	-0.36	1.0	-0.35	-0.36	-0.26	-0.42	-0.44	-0.2	-0.26
Common Stock Shares Outstanding	0.86	0.83	0.94	-0.31	-0.96	0.61	-0.49		0.77	0.78	0.68	0.91	0.68	0.78	0.83	0.62	0.51	0.89	-0.48	0.82	0.55	0.72	0.95	0.94	0.58	0.78
Total Liab	0.62	0.86	0.84	0.05	-0.84	0.29	-0.03	0.77		0.82	0.36	0.73	0.29	0.82	0.84	0.28	0.93	0.66	-0.01	0.81	0.35	0.6	0.81	0.78	0.37	0.8
Property Plant And Equipment Gross	0.68	0.83	0.82	0.03	-0.83	0.28	-0.23	0.78	0.82		0.36	0.77	0.43	1.0	0.99	0.28	0.67	0.66	-0.21	0.84	0.17	0.61	0.83	0.77	0.46	0.92
Total Current Assets	0.92	0.27	0.63	-0.89	-0.56	0.99	-0.33	0.68	0.36	0.36		0.79	0.97	0.39	0.46	0.99	0.11	0.79	-0.33	0.44	0.71	0.73	0.7	0.79	0.91	0.51
Other Current Liab	0.94	0.76	0.9	-0.45	-0.86	0.73	-0.45	0.91	0.73	0.77	0.79		0.8	0.79	0.84	0.73	0.49	0.89	-0.44	0.74	0.63	0.85	0.93	0.97	0.76	0.85
Total Stockholder Equity	0.93	0.27	0.61	-0.86	-0.55	0.96	-0.41	0.68	0.29	0.43	0.97	0.8		0.46	0.52	0.96	0.02	0.78	-0.41	0.43	0.63	0.74	0.7	0.78	0.92	0.56
Property Plant And Equipment Net	0.7	0.83	0.82	0.0	-0.83	0.31	-0.24	0.78	0.82	1.0	0.39	0.79	0.46		1.0	0.3	0.68	0.68	-0.21	0.81	0.19	0.66	0.83	0.79	0.49	0.93
Non Current Assets Total	0.76	0.84	0.86	-0.07	-0.86	0.38	-0.27	0.83	0.84	0.99	0.46	0.84	0.52	1.0		0.38	0.67	0.73	-0.25	0.83	0.26	0.7	0.87	0.84	0.54	0.94
Cash And Short Term Investments	0.89	0.17	0.56	-0.93	-0.48	1.0	-0.3	0.62	0.28	0.28	0.99	0.73	0.96	0.3	0.38		0.02	0.71	-0.3	0.38	0.68	0.66	0.64	0.72	0.9	0.44
Non Current Liabilities Total	0.36	0.71	0.58	0.26	-0.63	0.03	0.23	0.51	0.93	0.67	0.11	0.49	0.02	0.68	0.67	0.02		0.43	0.25	0.58	0.18	0.48	0.56	0.53	0.14	0.63
Other Stockholder Equity	0.87	0.66	0.82	-0.47	-0.88	0.71	-0.36	0.89	0.66	0.66	0.79	0.89	0.78	0.68	0.73	0.71	0.43		-0.34	0.63	0.59	0.82	0.85	0.89	0.7	0.7
Common Stock	-0.35	-0.4	-0.38	0.17	0.28	-0.29	1.0	-0.48	-0.01	-0.21	-0.33	-0.44	-0.41	-0.21	-0.25	-0.3	0.25	-0.34		-0.32	-0.36	-0.25	-0.4	-0.42	-0.19	-0.24
Accounts Payable	0.69	0.81	0.92	-0.07	-0.82	0.38	-0.35	0.82	0.81	0.84	0.44	0.74	0.43	0.81	0.83	0.38	0.58	0.63	-0.32		0.41	0.4	0.89	0.81	0.46	0.82
Non Currrent Assets Other	0.63	0.34	0.49	-0.55	-0.47	0.69	-0.36	0.55	0.35	0.17	0.71	0.63	0.63	0.19	0.26	0.68	0.18	0.59	-0.36	0.41		0.58	0.63	0.68	0.46	0.26
Other Current Assets	0.82	0.56	0.62	-0.45	-0.69	0.67	-0.26	0.72	0.6	0.61	0.73	0.85	0.74	0.66	0.7	0.66	0.48	0.82	-0.25	0.4	0.58		0.75	0.82	0.65	0.62
Good Will	0.89	0.82	0.96	-0.33	-0.92	0.64	-0.42	0.95	0.81	0.83	0.7	0.93	0.7	0.83	0.87	0.64	0.56	0.85	-0.4	0.89	0.63	0.75		0.98	0.63	0.82
Intangible Assets	0.94	0.78	0.92	-0.43	-0.89	0.73	-0.44	0.94	0.78	0.77	0.79	0.97	0.78	0.79	0.84	0.72	0.53	0.89	-0.42	0.81	0.68	0.82	0.98		0.71	0.81
Other Assets	0.89	0.22	0.6	-0.82	-0.49	0.9	-0.2	0.58	0.37	0.46	0.91	0.76	0.92	0.49	0.54	0.9	0.14	0.7	-0.19	0.46	0.46	0.65	0.63	0.71		0.66
Property Plant Equipment	0.77	0.79	0.84	-0.15	-0.78	0.45	-0.26	0.78	0.8	0.92	0.51	0.85	0.56	0.93	0.94	0.44	0.63	0.7	-0.24	0.82	0.26	0.62	0.82	0.81	0.66

Click cells to compare fundamentals

Cytosorbents Crp Account Relationship Matchups

Cytosorbents Crp fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	27.4M	90.0M	89.5M	63.2M	53.3M	55.9M
Short Long Term Debt Total	16.1M	1.0M	13.8M	18.3M	18.3M	19.2M
Total Current Liabilities	9.9M	10.2M	13.7M	9.7M	14.5M	15.3M
Net Debt	3.9M	(70.4M)	(38.3M)	(3.9M)	4.2M	4.4M
Retained Earnings	(188.8M)	(196.6M)	(221.2M)	(254.0M)	(282.5M)	(268.4M)
Cash	12.2M	71.4M	52.1M	22.1M	14.1M	13.2M
Common Stock Total Equity	32.6K	43.2K	43.5K	43.6K	39.3K	51.6K
Common Stock Shares Outstanding	32.3M	38.8M	43.4M	43.6M	44.7M	46.9M
Liabilities And Stockholders Equity	27.4M	90.0M	89.5M	63.2M	53.3M	55.9M
Total Liab	24.0M	10.7M	26.9M	27.9M	30.0M	31.5M
Property Plant And Equipment Gross	3.0M	3.1M	18.6M	23.3M	25.2M	26.4M
Total Current Assets	20.9M	82.5M	64.3M	33.8M	25.7M	17.6M
Accumulated Other Comprehensive Income	526.0K	(1.7M)	525.6K	2.3M	529.3K	555.8K
Other Current Liab	5.6M	7.0M	9.5M	7.9M	6.4M	6.7M
Total Stockholder Equity	3.4M	79.2M	62.6M	35.4M	23.3M	12.9M
Property Plant And Equipment Net	3.0M	3.1M	18.6M	23.3M	22.1M	23.2M
Non Current Assets Total	6.5M	7.5M	25.2M	29.5M	27.6M	28.9M
Cash And Short Term Investments	12.2M	71.4M	52.1M	22.1M	14.1M	14.1M
Non Current Liabilities Total	14.0M	582K	13.3M	18.1M	15.4M	16.2M
Other Stockholder Equity	191.6M	277.5M	283.2M	287.0M	305.2M	160.4M
Common Stock	32.6K	43.2K	43.5K	43.6K	54.2K	53.5K
Accounts Payable	2.0M	1.8M	2.8M	1.7M	3.8M	4.0M
Non Currrent Assets Other	3.5M	4.3M	1.9M	1.7M	1.5M	1.2M
Other Current Assets	2.1M	3.2M	2.9M	5.0M	1.8M	1.2M
Good Will	1.8M	2.6M	3.4M	4.2M	4.9M	5.1M
Intangible Assets	3.4M	4.2M	4.7M	4.4M	3.9M	4.1M
Other Assets	123.5K	5.4M	6.6M	1.7M	2.0M	1.1M
Property Plant Equipment	3.0M	2.1M	18.6M	10.7M	12.4M	13.0M
Long Term Debt	6.0M	9.3M	13.4M	5M	2.5M	3.8M
Net Receivables	4.5M	5.2M	4.5M	5.7M	6.1M	6.4M
Retained Earnings Total Equity	(188.8M)	(196.6M)	(221.2M)	(254.0M)	(228.6M)	(217.2M)
Inventory	2.1M	2.7M	4.8M	3.5M	3.7M	1.9M
Short Term Debt	2.1M	447.5K	570.6K	108.9K	2.9M	3.0M
Net Tangible Assets	56.6K	79.2M	62.6M	35.4M	40.7M	23.3M
Capital Surpluse	191.6M	277.5M	283.2M	287.0M	330.1M	215.6M
Short Long Term Debt	4M	666.7K	1.7M	2.5M	2.9M	1.8M

Pair Trading with Cytosorbents Crp

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytosorbents Crp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytosorbents Crp will appreciate offsetting losses from the drop in the long position's value.

Moving against Cytosorbents Stock

0.79	MD	Mednax Inc	Pair Corr
0.79	ECOR	Electrocore LLC	Pair Corr
0.72	ELMD	Electromed	Pair Corr
0.69	VREX	Varex Imaging Corp	Pair Corr
0.66	DXCM	DexCom Inc	Pair Corr

The ability to find closely correlated positions to Cytosorbents Crp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytosorbents Crp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytosorbents Crp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytosorbents Crp to buy it.

The correlation of Cytosorbents Crp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytosorbents Crp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytosorbents Crp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Cytosorbents Crp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Cytosorbents Crp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytosorbents Crp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytosorbents Crp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytosorbents Crp Stock:

How To Invest In Cytosorbents

Details

Is Cytosorbents Stock a good investment?

Details

What is Cytosorbents Crp's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.

You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.36)

Revenue Per Share

0.72

Quarterly Revenue Growth

0.066

Return On Assets

(0.28)

Return On Equity

(1.19)

The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cytosorbents Begin Period Cash Flow vs Capital Expenditures Analysis

Begin Period Cash Flow vs Capital Expenditures

Begin Period Cash Flow vs Capital Expenditures Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Capital Expenditures

Cytosorbents Crp fundamental ratios Correlations

Cytosorbents Crp Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cytosorbents Crp fundamental ratios Accounts

Pair Trading with Cytosorbents Crp

Moving against Cytosorbents Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Property Plant And Equipment Net	+ 1.0	Property Plant And Equipment Gross
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Cash
Non Current Assets Total	+ 0.99	Property Plant And Equipment Gross

Common Stock Shares Outstanding	- 0.96	Retained Earnings
Cash And Short Term Investments	- 0.93	Net Debt
Cash	- 0.93	Net Debt
Retained Earnings	- 0.93	Total Current Liabilities
Good Will	- 0.92	Retained Earnings
Intangible Assets	- 0.89	Retained Earnings